There’s no shortage of competition on the Covid-19 vaccine market, and things aren’t made easier for Danish biotech firm Bavarian Nordic by competitors being some of the biggest players in the world – remaining so even after a year and some time since the first vaccines against Covid-19 hit the market.
Last week, Bavarian Nordic publicized phase II data on its candidate, ABNCoV2, reporting generally positive news. Should everything go according to plan, the firm should have an approved vaccine, backed by the Danish government, ready for the market in 2023.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Director of Toxicology 
Key Account Manager, Europe and Asia 
Laboratory technician for process development and clinical manufacturing 
Client Talent Acquisition Specialist 
Consultant Manager 
Analytical Coordinator for Analytical Development 
Communications Consultant 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Senior Manager, Clinical Trial Budget 
Director Global Engineering 
(Senior) Drug Substance Specialist 
Account Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Senior Chemical Safety Advisor 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Clinical Trial Manager for development of in vitro diagnostics 
Senior Project Manager (GMP - Life Science) 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office